A spin-out from the Erasmus Medical Center in the Netherlands has raised seed funding to discover and develop new T cell therapies for solid tumours including triple negative breast cancer. The company, Pan Cancer T BV, will be investigating T cell therapies which have been equipped with new receptors enabling them to target specific cancer antigens. The group of therapies is known as T cell receptor (TCR) T cells.
